Matthew (Matt) Hobson, PhD is a Principal at Catalio Capital Management LP where he primarily covers investments in therapeutics and diagnostics for their venture and private credit strategies.
He currently represents Catalio on the board of Lassen Therapeutics and as a board observer of Anagenex, Iambic Therapeutics, Octant Therapeutics, and Pink Dx.
Matt joined Catalio at its founding in 2020. Prior to joining Catalio, Matthew was a Postdoctoral Fellow at the Johns Hopkins School of Medicine where he also earned a PhD in biophysics and biophysical chemistry, applying a variety of structural, biochemical and protein engineering methods to study proteins involved in DNA replication and repair. Matt also holds a B.S. in chemistry and physics from Emory University.